Farmas USA

LLY

After ph3 failures, Lilly signs new Alzheimer’s drug pact with AstraZeneca

http://www.fiercebiotech.com/biotech/after-ph3-failures-lilly-signs-new-alzheimer-s-drug-pact-astrazeneca

MSTX

Mast Therapeutics Announces Initiation Of Patient Enrollment In Additional Phase 2 Study Of AIR001 For The Treatment Of Heart Failure With Preserved Ejection Fraction

http://www.marketwatch.com/story/mast-therapeutics-announces-initiation-of-patient-enrollment-in-additional-phase-2-study-of-air001-for-the-treatment-of-heart-failure-with-preserved-ejection-fraction-2016-12-06?mod=mw_share_twitter

The Trump Rally: Phamaceutical Edition
We think that the pharmaceutical industry represents the best risk reward heading into 2017.

We would normally have said that industrials would be your best opportunity heading into the new year, but we actually believe pharmaceuticals are for two reasons,

1. Industrials have already rallied significantly since Trump won the election, as seen in the below chart

2. The risk reward profile of pharmaceutical companies is far better than industrials
http://seekingalpha.com/article/4029413-forget-trump-pharmaceuticals-offer-tremendous-risk-reward-2017?app=1&auth_param=ft8lg:1c4la57:204e6e345d719037e961e62e951312bb&uprof=37#alt2

HZNP

parece que busca esos 13 medios que te comenté, era muy de libro pararla en lo mismo de siempre la mm200 y la tendencia y más después de un pinchazo.

SGYP halted
Fase 3 positiva

SGYP

Preliminary Analysis Indicates Both Plecanatide 3 Mg and 6 Mg Doses Met the Primary Endpoint and Showed Statistical Significance

We look forward to the results of our second phase 3 IBS-C trial with plecanatide later this month

http://ploutuscharts.com/live-news-updates-trade-signals/

La estaba esperando para largo y se me ha escapado :(

AMRN llegando a los 20k scripts semanales